These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 28722177)

  • 21. Gemcitabine-based chemogene therapy for pancreatic cancer using Ad-dCK::UMK GDEPT and TS/RR siRNA strategies.
    Réjiba S; Bigand C; Parmentier C; Hajri A
    Neoplasia; 2009 Jul; 11(7):637-50. PubMed ID: 19568409
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Acquired resistance of pancreatic cancer cells towards 5-Fluorouracil and gemcitabine is associated with altered expression of apoptosis-regulating genes.
    Shi X; Liu S; Kleeff J; Friess H; Büchler MW
    Oncology; 2002; 62(4):354-62. PubMed ID: 12138244
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Competitive Binding Between Id1 and E2F1 to Cdc20 Regulates E2F1 Degradation and Thymidylate Synthase Expression to Promote Esophageal Cancer Chemoresistance.
    Li B; Xu WW; Guan XY; Qin YR; Law S; Lee NP; Chan KT; Tam PY; Li YY; Chan KW; Yuen HF; Tsao SW; He QY; Cheung AL
    Clin Cancer Res; 2016 Mar; 22(5):1243-55. PubMed ID: 26475334
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interaction between gemcitabine and topotecan in human non-small-cell lung cancer cells: effects on cell survival, cell cycle and pharmacogenetic profile.
    Giovannetti E; Mey V; Danesi R; Basolo F; Barachini S; Deri M; Del Tacca M
    Br J Cancer; 2005 Feb; 92(4):681-9. PubMed ID: 15700043
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Significant antitumor activity of cationic multilamellar liposomes containing human interferon-beta gene in combination with 5-fluorouracil against human renal cell carcinoma.
    Yamamoto K; Mizutani Y; Nakanishi H; Fujiwara J; Ishida H; Toiyama D; Abe K; Hayashi I; Okada K; Kawauchi A; Mizuno M; Yoshida J; Miki T
    Int J Oncol; 2008 Sep; 33(3):565-71. PubMed ID: 18695887
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A phase II study of capecitabine and cisplatin (XP) as first-line chemotherapy in patients with advanced esophageal squamous cell carcinoma.
    Lee J; Im YH; Cho EY; Hong YS; Lee HR; Kim HS; Kim MJ; Kim K; Kang WK; Park K; Shim YM
    Cancer Chemother Pharmacol; 2008 Jun; 62(1):77-84. PubMed ID: 17762932
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Thymidine Kinase 1 Loss Confers Trifluridine Resistance without Affecting 5-Fluorouracil Metabolism and Cytotoxicity.
    Edahiro K; Iimori M; Kobunai T; Morikawa-Ichinose T; Miura D; Kataoka Y; Niimi S; Wakasa T; Saeki H; Oki E; Kitao H; Maehara Y
    Mol Cancer Res; 2018 Oct; 16(10):1483-1490. PubMed ID: 29866926
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Low-dose all-trans retinoic acid enhances cytotoxicity of cisplatin and 5-fluorouracil on CD44(+) cancer stem cells.
    Najafzadeh N; Mazani M; Abbasi A; Farassati F; Amani M
    Biomed Pharmacother; 2015 Aug; 74():243-51. PubMed ID: 26349992
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cooperative inhibitory effect of sinomenine combined with 5-fluorouracil on esophageal carcinoma.
    Wang J; Yang ZR; Dong WG; Zhang JX; Guo XF; Song J; Qiu S
    World J Gastroenterol; 2013 Dec; 19(45):8292-300. PubMed ID: 24363520
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase II trial of gemcitabine, 5-fluorouracil and leucovorin in advanced esophageal carcinoma.
    Morgan-Meadows S; Mulkerin D; Berlin JD; Kim K; Bailey H; Saphner T; Jumonville A; Hansen R; Ahuja H; McFarland T; Thomas JP
    Oncology; 2005; 69(2):130-4. PubMed ID: 16118509
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synergistic growth suppression induced in esophageal squamous cell carcinoma cells by combined treatment with docetaxel and heavy carbon-ion beam irradiation.
    Kitabayashi H; Shimada H; Yamada S; Yasuda S; Kamata T; Ando K; Tsujii H; Ochiai T
    Oncol Rep; 2006 Apr; 15(4):913-8. PubMed ID: 16525679
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Induction of pancreatic cancer cell apoptosis, invasion, migration, and enhancement of chemotherapy sensitivity of gemcitabine, 5-FU, and oxaliplatin by hnRNP A2/B1 siRNA.
    Gu WJ; Liu HL
    Anticancer Drugs; 2013 Jul; 24(6):566-76. PubMed ID: 23525071
    [TBL] [Abstract][Full Text] [Related]  

  • 33. UCN-01 (7-hydroxystaurosporine) enhances 5-fluorouracil cytotoxicity through down-regulation of thymidylate synthetase messenger RNA.
    Abe S; Kubota T; Otani Y; Furukawa T; Watanabe M; Kumai K; Kitajima M
    Jpn J Cancer Res; 2000 Nov; 91(11):1192-8. PubMed ID: 11092986
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metformin Inhibited Proliferation and Metastasis of Colorectal Cancer and presented a Synergistic Effect on 5-FU.
    Sang J; Tang R; Yang M; Sun Q
    Biomed Res Int; 2020; 2020():9312149. PubMed ID: 32851092
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The nm23-H1 gene as a predictor of sensitivity to chemotherapeutic agents in oesophageal squamous cell carcinoma.
    Iizuka N; Hirose K; Noma T; Hazama S; Tangoku A; Hayashi H; Abe T; Yamamoto K; Oka M
    Br J Cancer; 1999 Oct; 81(3):469-75. PubMed ID: 10507772
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Establishment of 5-fluorouracil-resistant oral squamous cell carcinoma cell lines with epithelial to mesenchymal transition changes.
    Harada K; Ferdous T; Ueyama Y
    Int J Oncol; 2014 Apr; 44(4):1302-8. PubMed ID: 24452635
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients.
    Mey V; Giovannetti E; De Braud F; Nannizzi S; Curigliano G; Verweij F; De Cobelli O; Pece S; Del Tacca M; Danesi R
    Br J Cancer; 2006 Aug; 95(3):289-97. PubMed ID: 16868547
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synergistic antitumor effect of combined 5-fluorouracil (5-FU) with 5-chloro-2,4-dihydroxypyridine on 5-FU-resistant gastric cancer cells: possible role of a dihydropyrimidine dehydrogenase-independent mechanism.
    Sasaki E; Tominaga K; Kuwamura H; Watanabe T; Fujiwara Y; Oshitani N; Higuchi K; Arakawa T
    J Gastroenterol; 2007 Oct; 42(10):816-22. PubMed ID: 17940834
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting Casein Kinase 1 Delta Sensitizes Pancreatic and Bladder Cancer Cells to Gemcitabine Treatment by Upregulating Deoxycytidine Kinase.
    Vena F; Bayle S; Nieto A; Quereda V; Aceti M; Frydman SM; Sansil SS; Grant W; Monastyrskyi A; McDonald P; Roush WR; Teng M; Duckett D
    Mol Cancer Ther; 2020 Aug; 19(8):1623-1635. PubMed ID: 32430484
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Schedule-dependent therapeutic effects of gemcitabine combined with uracil-tegafur in a human pancreatic cancer xenograft model.
    Tsujie M; Nakamori S; Nakahira S; Takeda S; Takahashi Y; Hayashi N; Okami J; Nagano H; Dono K; Umeshita K; Sakon M; Monden M
    Pancreas; 2006 Aug; 33(2):142-7. PubMed ID: 16868479
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.